ProCE Banner Activity


Acclimating Practice to the Current Treatment Landscape in Follicular Lymphoma: Emerging Evidence and Recent Results


Watch this on-demand webcast featuring Ian W. Flinn, MD, PhD, and Laurie H. Sehn, MD, MPH, discussing the latest clinical data informing optimal management of relapsed/refractory follicular lymphoma, including new data from ASH 2022.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: March 10, 2023

Expiration: March 09, 2024

Begin Activity



Ian W. Flinn

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

Laurie H. Sehn

Laurie H. Sehn, MD, MPH

Chair, Lymphoma Tumour Group
BC Cancer
Vancouver, Canada

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from

Genentech, a member of the Roche Group

MEI Pharma Inc

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with Follicular Lymphoma, including hematologists/oncologists, advanced care practitioners, pharmacists, and nurses.

Program Learning Goal

The goal of this activity is to improve the knowledge, confidence, and competence of HCPs treating patients with relapsed/refractory follicular lymphoma by leveraging recent and emerging data that must be considered in treatment decisions.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Incorporate safety and efficacy data on novel and emerging therapies into management plans for patients with relapsed/refractory follicular lymphoma 

  • Plan the optimal sequence of PI3K inhibitors, epigenetic modifiers, CAR T-cell therapy, and antibodies for patients with relapsed/refractory follicular lymphoma based on available evidence, as well as guideline and expert recommendations

  • Manage adverse events associated with novel treatment regimens in relapsed/refractory follicular lymphoma 

  • Identify patients with relapsed/refractory follicular lymphoma who are eligible for enrollment on a clinical trial


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Ian W. Flinn, MD, PhD: consultant (paid to institution): AbbVie, AstraZeneca, BeiGene, Century Therapeutics, Genentech, Genmab, Hutchison MediPharma, Iksuda, InnoCare Pharma, Janssen, Kite, MorphoSys, Myeloid, Novartis, Nurix, Pharmacyclics, Roche, Secura Bio, Servier, Takeda, TG Therapeutics, Verastem, Vincerx, Xencor; researcher (paid to institution): 2seventy bio, AbbVie, Acerta, Agios, ArQule, AstraZeneca, BeiGene, Biopath, Bristol-Myers Squibb, CALIBR, CALGB, Celgene, City of Hope National Medical Center, Constellation, Curis, CTI Biopharma, Epizyme, Fate, Forma, Forty Seven, Genentech, Gilead Sciences, InnoCare, IGM Biosciences, Incyte, Infinity, Janssen, Kite Pharma, Loxo, Merck, Millennium, MorphoSys, Myeloid, Novartis, Nurix, Pfizer, Pharmacyclics, Portola, Rhizen, Roche, Seattle Genetics, Tessa Therapeutics, TCR2 Therapeutics, TG Therapeutics, Trillium, Triphase Research & Development Corp, Unum Therapeutics, Verastem.

Laurie H. Sehn, MD, MPH: consultant/advisor/speaker: AbbVie, AstraZeneca, Celgene/Bristol-Myers Squibb, Gilead/Kite, Incyte, Janssen, Merck, Roche/Genentech, Seattle Genetics, Teva, TG Therapeutics.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from March 10, 2023, through March 09, 2024:

  1. Create an account or Login at
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 


Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.